CA
NZ
UK
AU
IND
US
BioNTech (NASDAQ:BNTX) announced on October 13, 2026 that a head-and-neck cancer trial did not meet the first of its two primary endpoints, PFS. The overall survival endpoint remains open and the data are still maturing. The drug under study, the patient numbers, the hazard …
An analyst initiated coverage of Gossamer Bio (NASDAQ:GOSS) with a Buy rating and a USD 160 target on October 13, 2026. The firm, the stock price at the time and the investment case were not captured in the information gathered, so the implied upside …
UnitedHealth Group (NYSE:UNH) reported third-quarter results on October 13, 2026. Adjusted EPS of USD 4.69 compared with roughly USD 4.15 expected, and revenue of USD 112.7 billion was down 0.4% year over year but above estimates. Management raised 2026 adjusted EPS guidance to at …
Johnson & Johnson (NYSE:JNJ) reported third-quarter sales of USD 25.4 billion, up 5.9%, on October 13, 2026 and lifted its full-year adjusted EPS outlook to USD 11.05 to USD 11.15. Even so, the shares fell between 5.34% and 6% at the close, after opening …
UnitedHealth Group (NYSE:UNH) reported third-quarter EPS of USD 4.69 on October 13, 2026, against a consensus of USD 4.06, and raised its 2026 EPS guidance to at least USD 20.50. The beat of USD 0.63 a share is about 15.5% above the estimate, simple …
Syndax Pharmaceuticals (NASDAQ:SNDX) announced on October 13, 2026 that its axatilimab trial in lung disease missed the Phase 2 primary endpoint and that the trials were discontinued. The shares fell more than 17%, the stock's sharpest one-day drop since May 2025. Axatilimab is an …
Shares of Pinnacle Food Group Limited climbed about 80% on Tuesday to close at $4.70, with volume well above average. The spark was news that its subsidiary completed the first bench-scale fermentation of its first-generation recombinant human lactoferrin (rhLF) yeast strain in a 5-liter …
SCWorx Corp. fell about 22% on Tuesday to close at $2.46, a volatile stretch since the healthcare data-management software company regained Nasdaq compliance and resumed trading after a multi-month suspension. Pre-market today the stock was down roughly 11% near $2.18. Selling pressure reflects dilution …
Nexalin Technology, Inc. declined about 21% on Tuesday to close at $2.64, continuing a longer downtrend for the medical-device micro-cap focused on neurostimulation products. Pre-market today the stock was roughly flat to slightly lower near $2.61. The stock remains under pressure from ongoing losses, …
Capricor Therapeutics, Inc. (NASDAQ:CAPR)'s second quarter reflected continuedInvestmentin its Deramiocel regulatory program as the company's net loss widened from a year earlier. Management said it is continuing to work with the FDA on a path forward for theBiologicsLicense Application following a July 29, 2026 …
Please wait processing your request...